Agreement will allow production of Soberana 02 vaccine in Italy

Havana, April 29 (RHC)-- The production of Cuba's Soberana 02 anti-Covid-19 vaccine will be carried out in Italy after the signing of an agreement at the BioHabana 2022 International Congress.

The trilateral agreement was signed by the Finlay Vaccine Institute (IFV) the author of the immunogen; Antonio Dinaro, president of the Adienne company; and the leader of the Italian Agency for Cultural and Economic Exchange with Cuba, Michele Curto.

The Director-General of the Finlay Institute, Vicente Vérez Bencomo, explained that this alliance seeks, in the first phase, to formulate, fill and package the immunizer by the Italian-Swiss entity Adienne and, in the second phase, to evaluate the total manufacturing of that preparation and others of the IFV.

Soberana 02 is specially designed for children and was able to demonstrate in clinical trials all the advantages of conjugated vaccines for the pediatric population, he said.

Vérez also said that this product has a phase III and IV concluded because it has a massive application that showed a high safety, and an evaluation of the impact of this administration, which makes it a unique option in the world.

In reference to its safety, the specialist said that for months it has had all the evidence of safety, immunogenicity and efficacy to be used in children from 2 to 5 years of age.